Coverage of Buprenorphine Medications That Treat Opioid Use Disorder by State Medicaid Programs

Authors: Amanda Mauri, MPH | Victoria Schoebel | Caitlyn Wayment | Jessica Buche, MPH, MA | Angela Beck, PhD, MPH

Topics: Behavioral Health, Data Analysis, Medicaid

Research Center: Behavioral Health Workforce Research Center

February 2, 2021

Buprenorphine is shown to be an effective medication for the treatment of opioid use disorder. It promotes long-term recovery and decreases the risk of mortality. Although Medicaid programs largely cover buprenorphine products, many continue to apply prior authorization (PA) requirements.

This report studies how state Medicaid programs apply PA requirements to buprenorphine products.

Read Report
Behavioral Health Workforce Research Center logo